Generative AI advances to reshape health care
By not only tackling high costs but also elevating patient experiences by enhancing efficiency and outcomes, this technology stands ready to revolutionize many aspects of the industry, says GlobalData.
New Search
If you are not happy with the results below please do another search
Search
50 search results for:
FDA approves new treatment for UTIs
/in Therapeutics/by AdministratorYesterday that FDA approved Pivya (pivmecillinam) tablets for the treatment of female adults with uncomplicated urinary tract infections (UTIs) caused by susceptible isolates of Escherichia coli, Proteus mirabilis and Staphylococcus saprophyticus.
Sanders launches probe of ‘outrageously high prices’ of Novo’s Ozempic, Wegovy
/in Business, Therapeutics/by BioSpaceSen. Bernie Sanders (I-Vt.) on Wednesday launched an investigation into the exorbitant prices of Novo Nordisk’s Ozempic and Wegovy blockbusters, and has asked the Danish drugmaker to justify their price tags.
Regeneron to collaborate on gene editing therapies with Doudna-founded Mammoth
/in R&D, Therapeutics/by Reuters HealthMammoth’s CRISPR-based gene editing platform and Regeneron’s delivery technologies will be used to create disease-modifying medicines that can be delivered to tissues beyond the liver.
Merck raises 2024 profit forecast on strong sales of cancer drug Keytruda
/in Business, Therapeutics/by Reuters HealthThe New Jersey-based drugmaker said it expected earnings of $8.53 and $8.65 per share, up from its previous forecast of $8.44 to $8.59, and sales of $63.1-$64.3 billion for the year.
Ogilvy introduces global health influencer offering
/in Marketing & Advertising/by AdministratorNew Ogilvy survey shows 7 in 10 people either follow or seek out health content or learn about health/medical issues from social media – and a vast majority of those who engage take some form of action.
Biogen cost cuts drive profit beat, Alzheimer’s drug sales jump
/in Business, Therapeutics/by Reuters HealthBiogen beat market estimates for first-quarter profit on Wednesday as a series of cost-cutting measures helped offset the impact of fierce competition for its older drugs, sending its shares up nearly 7% before the bell.
Roche trims four early assets as Q1 sales slip 6 percent on currency, COVID headwinds
/in Business, Therapeutics/by BioSpaceDespite being hit with a continuing decline in COVID-19 sales and a strong Swiss franc, Roche on Wednesday reported first-quarter sales were up 2% at constant exchange rates.
Day One’s Ojemda gets FDA accelerated approval for pediatric brain tumor
/in Therapeutics/by BioSpaceThe FDA on Tuesday approved Day One Biopharmaceuticals’ type II RAF inhibitor Ojemda, which is designed to penetrate the blood-brain barrier, for the treatment of relapsed or refractory pediatric low-grade glioma.
BMS initiates first round of layoffs in New Jersey
/in Business, Therapeutics/by BioSpaceThe company has resumed dismissing employees as part of an ongoing workforce reduction of about 10%.
